Clearmind Medicine announces publication of European patent application

Clearmind Medicine (CMND) announced the official publication of a European patent application by the European Patent Office. This patent, numbered EP 4531826, covers Clearmind’s proprietary psychedelic-based combination therapy, which includes MEAI and certain N-Acylethanolamines, such as Palmitoylethanolamide, for the treatment of cocaine addiction. The application further strengthens Clearmind’s expanding global intellectual property portfolio and complements similar patent filings in other key markets. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings. Further research was conducted in rats to assess whether MEAI’s effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards such as sucrose. This finding suggests that MEAI’s impact on drug cravings is not tied to the general reward system, but is specifically targeted at drug-related compulsions. The patent application is part of Clearmind’s ongoing collaboration with SciSparc Ltd. (SPRC), with the aim to explore the combined potential of MEAI and SciSparc’s PEA-based technologies for treating various central nervous system disorders.